Edwards Lifesciences (EW) Revenue — Quarter Ended Sep 30, 2024
Revenue for the quarter was slightly lower than the prior quarter. Compared with the same quarter last year, revenue increased.
Key takeaway
Quarter ended Sep 30, 2024 · FY2024 Q3
Revenue for the quarter was slightly lower than the prior quarter. Compared with the same quarter last year, revenue increased.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$1.4B
Revenue reported for this quarter.
Quarter-over-quarter
-1.1%
Change from the immediately preceding quarter.
Year-over-year
+11.9%
Change from the comparable year-ago quarter.
Trailing four quarters
$5.3B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2023 | $1.3B | +194.6% |
| Mar 31, 2024 | $1.3B | +8.9% |
| Jun 30, 2024 | $1.4B | +4.4% |
| Sep 30, 2024 | $1.4B | +11.9% |
Revenue performance
The reported revenue reflects a sequential decline from the immediately preceding quarter. However, on a year-over-year basis, revenue expanded.
Quarterly comparison
The quarter's revenue was down compared to the prior three-month period, but up versus the same quarter one year earlier. The trailing twelve-month revenue stood at a certain level.
What to watch
The sequential decline in revenue may warrant attention in the next reporting period.